Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronic iloprost administration in scleroderma: effect on skin fibrosis progression
2004-002712-28Phase 3Terminated
- Sponsor
- Italfarmaco
- Start
- Feb 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of iloprost in systemic sclerosis (SSc) (2 arms), sponsored by Italfarmaco. Primary endpoint: Change in skin fibrosis. Started Feb 2006; status: terminated.
02
Drugs
iloprost
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2004-002712-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002712-28.